A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects
Latest Information Update: 11 Mar 2025
At a glance
- Drugs WD 890 (Primary)
- Indications Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ningbo Wenda Pharma
Most Recent Events
- 07 Mar 2025 Status changed from recruiting to completed.
- 25 Jul 2024 New trial record